JP2000506133A - 薬剤由来の毒性を減少させることができる酸化窒素供与体 - Google Patents
薬剤由来の毒性を減少させることができる酸化窒素供与体Info
- Publication number
- JP2000506133A JP2000506133A JP9530576A JP53057697A JP2000506133A JP 2000506133 A JP2000506133 A JP 2000506133A JP 9530576 A JP9530576 A JP 9530576A JP 53057697 A JP53057697 A JP 53057697A JP 2000506133 A JP2000506133 A JP 2000506133A
- Authority
- JP
- Japan
- Prior art keywords
- formula
- drug
- compound
- drugs
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940079593 drug Drugs 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 231100000419 toxicity Toxicity 0.000 title claims abstract description 9
- 230000001988 toxicity Effects 0.000 title claims abstract description 9
- 239000002840 nitric oxide donor Substances 0.000 title claims description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 43
- 230000002496 gastric effect Effects 0.000 claims abstract description 16
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical group O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims abstract description 14
- 150000002484 inorganic compounds Chemical class 0.000 claims abstract description 8
- 229910010272 inorganic material Inorganic materials 0.000 claims abstract description 8
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 7
- 150000002894 organic compounds Chemical class 0.000 claims abstract description 5
- 238000000338 in vitro Methods 0.000 claims abstract description 4
- 238000000034 method Methods 0.000 claims description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 16
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 16
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 claims description 15
- 229960004316 cisplatin Drugs 0.000 claims description 15
- 239000000006 Nitroglycerin Substances 0.000 claims description 13
- 229960003711 glyceryl trinitrate Drugs 0.000 claims description 13
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 12
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 11
- 108010036949 Cyclosporine Proteins 0.000 claims description 11
- 229960001265 ciclosporin Drugs 0.000 claims description 11
- 229930182912 cyclosporin Natural products 0.000 claims description 11
- 230000003637 steroidlike Effects 0.000 claims description 11
- 108010061435 Enalapril Proteins 0.000 claims description 10
- 229960000873 enalapril Drugs 0.000 claims description 10
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 10
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 10
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 9
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 9
- 229960001259 diclofenac Drugs 0.000 claims description 9
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 9
- 229960004584 methylprednisolone Drugs 0.000 claims description 9
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 9
- 229940083618 sodium nitroprusside Drugs 0.000 claims description 9
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 8
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 8
- 229960004150 aciclovir Drugs 0.000 claims description 8
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 8
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical compound [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims description 8
- 239000003018 immunosuppressive agent Substances 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 7
- 229940041181 antineoplastic drug Drugs 0.000 claims description 7
- 229960002009 naproxen Drugs 0.000 claims description 7
- 231100000828 respiratory toxicity Toxicity 0.000 claims description 7
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 6
- 229960003957 dexamethasone Drugs 0.000 claims description 6
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 6
- 229940124589 immunosuppressive drug Drugs 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 6
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 5
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 5
- 229940127217 antithrombotic drug Drugs 0.000 claims description 5
- 239000003443 antiviral agent Substances 0.000 claims description 5
- 229960001680 ibuprofen Drugs 0.000 claims description 5
- 229960000905 indomethacin Drugs 0.000 claims description 5
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 5
- LBHIOVVIQHSOQN-UHFFFAOYSA-N nicorandil Chemical compound [O-][N+](=O)OCCNC(=O)C1=CC=CN=C1 LBHIOVVIQHSOQN-UHFFFAOYSA-N 0.000 claims description 5
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 4
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims description 4
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 claims description 4
- 229960000830 captopril Drugs 0.000 claims description 4
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 4
- 231100000414 gastrointestinal toxicity Toxicity 0.000 claims description 4
- 229960002460 nitroprusside Drugs 0.000 claims description 4
- 239000011505 plaster Substances 0.000 claims description 4
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims description 3
- 239000005541 ACE inhibitor Substances 0.000 claims description 3
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims description 3
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 3
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 3
- 229930182566 Gentamicin Natural products 0.000 claims description 3
- JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 claims description 3
- GNGMKRCJJRIBLW-UHFFFAOYSA-N P(=O)(O)(O)O.[N+](=O)(O)[O-].[N+](=O)(O)[O-].[N+](=O)(O)[O-] Chemical compound P(=O)(O)(O)O.[N+](=O)(O)[O-].[N+](=O)(O)[O-].[N+](=O)(O)[O-] GNGMKRCJJRIBLW-UHFFFAOYSA-N 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 239000003146 anticoagulant agent Substances 0.000 claims description 3
- 229960002274 atenolol Drugs 0.000 claims description 3
- 239000002876 beta blocker Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 229960003405 ciprofloxacin Drugs 0.000 claims description 3
- 229960004544 cortisone Drugs 0.000 claims description 3
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 3
- 229960004369 flufenamic acid Drugs 0.000 claims description 3
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 claims description 3
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 claims description 3
- 229960000588 flunixin Drugs 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 229960002518 gentamicin Drugs 0.000 claims description 3
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 3
- 229960000991 ketoprofen Drugs 0.000 claims description 3
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 3
- 229960004752 ketorolac Drugs 0.000 claims description 3
- 229960003464 mefenamic acid Drugs 0.000 claims description 3
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 claims description 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 3
- 229960002237 metoprolol Drugs 0.000 claims description 3
- 231100000417 nephrotoxicity Toxicity 0.000 claims description 3
- 229960000916 niflumic acid Drugs 0.000 claims description 3
- BRBAEHHXGZRCBK-UHFFFAOYSA-N pentrinitrol Chemical compound [O-][N+](=O)OCC(CO)(CO[N+]([O-])=O)CO[N+]([O-])=O BRBAEHHXGZRCBK-UHFFFAOYSA-N 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 229960005335 propanol Drugs 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 229960004605 timolol Drugs 0.000 claims description 3
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 claims description 2
- 229930105110 Cyclosporin A Natural products 0.000 claims description 2
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 claims description 2
- 230000003115 biocidal effect Effects 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- SUAJWTBTMNHVBZ-UHFFFAOYSA-N clonitrate Chemical compound [O-][N+](=O)OCC(CCl)O[N+]([O-])=O SUAJWTBTMNHVBZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- SNFOERUNNSHUGP-UHFFFAOYSA-N erythritol tetranitrate Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)C(O[N+]([O-])=O)CO[N+]([O-])=O SNFOERUNNSHUGP-UHFFFAOYSA-N 0.000 claims description 2
- 229940029575 guanosine Drugs 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- DGMJZELBSFOPHH-KVTDHHQDSA-N mannite hexanitrate Chemical compound [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)CO[N+]([O-])=O DGMJZELBSFOPHH-KVTDHHQDSA-N 0.000 claims description 2
- 229960001765 mannitol hexanitrate Drugs 0.000 claims description 2
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 claims description 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 238000003786 synthesis reaction Methods 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 210000000056 organ Anatomy 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 description 22
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 22
- 241000700159 Rattus Species 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 14
- 238000011534 incubation Methods 0.000 description 13
- 238000011282 treatment Methods 0.000 description 12
- 229940109239 creatinine Drugs 0.000 description 11
- 230000003907 kidney function Effects 0.000 description 11
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 10
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 10
- 229960002504 capsaicin Drugs 0.000 description 7
- 235000017663 capsaicin Nutrition 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000007170 pathology Effects 0.000 description 7
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 6
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 6
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 150000002829 nitrogen Chemical class 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000700198 Cavia Species 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 206010006482 Bronchospasm Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000007885 bronchoconstriction Effects 0.000 description 4
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 229960002497 nicorandil Drugs 0.000 description 3
- -1 nitrogen derivative compound Chemical class 0.000 description 3
- 206010034674 peritonitis Diseases 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 238000002266 amputation Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000002917 arthritic effect Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 229940125721 immunosuppressive agent Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-M 2-(6-methoxynaphthalen-2-yl)propanoate Chemical compound C1=C(C(C)C([O-])=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-M 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WMFYOYKPJLRMJI-UHFFFAOYSA-N Lercanidipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)(C)CN(C)CCC(C=2C=CC=CC=2)C=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 WMFYOYKPJLRMJI-UHFFFAOYSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000000642 iatrogenic effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- YZZCJYJBCUJISI-UHFFFAOYSA-N propatylnitrate Chemical compound [O-][N+](=O)OCC(CC)(CO[N+]([O-])=O)CO[N+]([O-])=O YZZCJYJBCUJISI-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 102220240796 rs553605556 Human genes 0.000 description 1
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960002485 trolnitrate Drugs 0.000 description 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Underground Structures, Protecting, Testing And Restoring Foundations (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT96MI000352A IT1282686B1 (it) | 1996-02-26 | 1996-02-26 | Composti in grado di ridurre la tossicita' da farmaci |
| IT96A000352 | 1996-02-26 | ||
| PCT/EP1997/000873 WO1997031654A1 (en) | 1996-02-26 | 1997-02-24 | Nitric oxide donors capable of reducing toxicity from drugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000506133A true JP2000506133A (ja) | 2000-05-23 |
| JP2000506133A5 JP2000506133A5 (enExample) | 2004-11-25 |
Family
ID=11373387
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9530576A Pending JP2000506133A (ja) | 1996-02-26 | 1997-02-24 | 薬剤由来の毒性を減少させることができる酸化窒素供与体 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7087588B2 (enExample) |
| EP (2) | EP0904110B1 (enExample) |
| JP (1) | JP2000506133A (enExample) |
| KR (1) | KR19990087113A (enExample) |
| AT (1) | ATE220920T1 (enExample) |
| AU (1) | AU706591B2 (enExample) |
| BR (1) | BR9707739A (enExample) |
| CA (1) | CA2247848C (enExample) |
| DE (1) | DE69714253T2 (enExample) |
| DK (1) | DK0904110T3 (enExample) |
| ES (1) | ES2180938T3 (enExample) |
| HU (1) | HUP9900993A3 (enExample) |
| IT (1) | IT1282686B1 (enExample) |
| PT (1) | PT904110E (enExample) |
| RU (1) | RU2192247C2 (enExample) |
| WO (1) | WO1997031654A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008501630A (ja) * | 2004-06-10 | 2008-01-24 | 日本化薬株式会社 | 抗癌剤の効果増強剤 |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6043232A (en) * | 1997-07-23 | 2000-03-28 | Nitromed, Inc. | Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs |
| US5703073A (en) * | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| GB9801398D0 (en) | 1998-01-22 | 1998-03-18 | Anggard Erik E | Chemical compounds |
| IT1298338B1 (it) * | 1998-03-05 | 1999-12-20 | Nicox Sa | Composizioni farmaceutiche per l'ulcera |
| EP1126838A4 (en) | 1998-10-30 | 2005-02-16 | Nitromed Inc | NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE |
| TWI243672B (en) * | 1999-06-01 | 2005-11-21 | Astrazeneca Ab | New use of compounds as antibacterial agents |
| TWI262791B (en) | 1999-10-27 | 2006-10-01 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
| US6552078B2 (en) | 1999-10-27 | 2003-04-22 | Nobex Corp | 6-methoxy-2-naphthylacetic acid prodrugs |
| US6436990B1 (en) | 1999-10-27 | 2002-08-20 | Nobex Corporation | 6-methoxy-2-naphthylacetic acid prodrugs |
| JP2003523958A (ja) | 1999-12-23 | 2003-08-12 | ニトロメド インコーポレーテッド | ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−２の阻害剤、組成物ならびに使用法 |
| AU2001234602A1 (en) * | 2000-01-26 | 2001-08-07 | Cedars-Sinai Medical Center | Method for using potassium channel agonists for delivering medicant to an abnormal brain region and/or a malignant tumor |
| US7018979B1 (en) | 2000-01-26 | 2006-03-28 | Cedars-Sinai Medical Center | Method for using potassium channel agonists for delivering a medicant to an abnormal brain region and/or a malignant tumor |
| CA2432642A1 (en) | 2000-12-21 | 2002-08-08 | Subhash P. Khanapure | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| EP1219306A1 (en) * | 2000-12-29 | 2002-07-03 | Nicox S.A. | Compositions comprising cyclodextrins and NO- releasing drugs |
| US7211561B2 (en) | 2001-10-12 | 2007-05-01 | Cedars-Sinai Medical Center | Method for inducing selective cell death of malignant cells by activation of calcium-activated potassium channels (KCa) |
| WO2003088961A1 (en) | 2002-04-19 | 2003-10-30 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Beta-agonist compounds comprising nitric oxide donor groups and reactive oxygen species scavenger groups and their use in the treatment of respiratory disorders |
| US7220749B2 (en) | 2002-06-11 | 2007-05-22 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| JP2005535642A (ja) | 2002-06-28 | 2005-11-24 | ニトロメッド インコーポレーティッド | オキシムおよび／またはヒドラゾンを含有するニトロソ化および／またはニトロシル化シクロオキシゲナーゼ−２選択的阻害剤、組成物、および使用方法 |
| JP2005539089A (ja) | 2002-07-03 | 2005-12-22 | ニトロメッド インコーポレーティッド | ニトロソ化非ステロイド性抗炎症化合物、組成物および使用方法 |
| CA2493156A1 (en) | 2002-07-29 | 2004-02-05 | Nitromed, Inc. | Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| SE0300971D0 (sv) * | 2003-04-03 | 2003-04-03 | Aga Ab | Nitric oxide in treatment of inflammation |
| AU2005206227A1 (en) * | 2004-01-27 | 2005-08-04 | Merck Frosst Company | Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events |
| JP2007325501A (ja) * | 2004-08-25 | 2007-12-20 | Tottori Univ | 非ステロイド性抗炎症薬による動物の消化管副作用の予防・治療方法 |
| EP2669269B1 (en) | 2005-05-27 | 2019-05-22 | The University of North Carolina At Chapel Hill | Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications |
| US20100240745A1 (en) * | 2009-03-20 | 2010-09-23 | Nicox S.A. | Method of treatment of inflammation in hypertensive patients |
| WO2011022652A1 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Topical gels |
| EP2467173B8 (en) | 2009-08-21 | 2019-06-19 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| WO2012118819A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same |
| JO3350B1 (ar) | 2011-03-07 | 2019-03-13 | Merck Sharp & Dohme | مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات |
| RU2539630C1 (ru) * | 2013-07-09 | 2015-01-20 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") | Способ профилактики ишемии сетчатки в эксперименте |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5570683A (en) | 1990-12-05 | 1996-11-05 | The General Hospital Corporation | Methods and devices for treating pulmonary vasoconstriction and asthma |
| IT1256345B (it) | 1992-08-20 | 1995-12-01 | Esteri nitrici di derivati dell'acido 2-(2,6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione | |
| IT1256450B (it) | 1992-11-26 | 1995-12-05 | Soldato Piero Del | Esteri nitrici con attivita' farmacologica e procedimento per la loro preparazione |
| JP3775796B2 (ja) | 1993-10-06 | 2006-05-17 | ニコックス エス エイ | 抗炎症活性及び／又は鎮痛活性を有する硝酸エステル類及びそれらの製造方法 |
| RU2145595C1 (ru) | 1994-05-10 | 2000-02-20 | Никокс С.А. | Нитроксисоединения и фармацевтическая композиция на их основе, имеющие противовоспалительную, анальгетическую и антитромбоцитарную активности |
| US5597809A (en) * | 1994-06-23 | 1997-01-28 | Massachusetts Eye & Ear Infirmary | Treatment of optic neuritis |
| US5703073A (en) | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
| US5620416A (en) | 1995-06-07 | 1997-04-15 | North Carolina State University | Methods of using topical agents with systemically administered active agents |
-
1996
- 1996-02-26 IT IT96MI000352A patent/IT1282686B1/it active IP Right Grant
-
1997
- 1997-02-24 AU AU20924/97A patent/AU706591B2/en not_active Ceased
- 1997-02-24 RU RU98117618/14A patent/RU2192247C2/ru not_active IP Right Cessation
- 1997-02-24 EP EP97906115A patent/EP0904110B1/en not_active Revoked
- 1997-02-24 JP JP9530576A patent/JP2000506133A/ja active Pending
- 1997-02-24 HU HU9900993A patent/HUP9900993A3/hu unknown
- 1997-02-24 ES ES97906115T patent/ES2180938T3/es not_active Expired - Lifetime
- 1997-02-24 BR BR9707739A patent/BR9707739A/pt not_active Application Discontinuation
- 1997-02-24 KR KR1019980706501A patent/KR19990087113A/ko not_active Ceased
- 1997-02-24 EP EP02008079A patent/EP1221326A3/en not_active Withdrawn
- 1997-02-24 CA CA002247848A patent/CA2247848C/en not_active Expired - Fee Related
- 1997-02-24 DE DE69714253T patent/DE69714253T2/de not_active Revoked
- 1997-02-24 PT PT97906115T patent/PT904110E/pt unknown
- 1997-02-24 AT AT97906115T patent/ATE220920T1/de not_active IP Right Cessation
- 1997-02-24 WO PCT/EP1997/000873 patent/WO1997031654A1/en not_active Ceased
- 1997-02-24 DK DK97906115T patent/DK0904110T3/da active
-
2004
- 2004-07-07 US US10/885,121 patent/US7087588B2/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008501630A (ja) * | 2004-06-10 | 2008-01-24 | 日本化薬株式会社 | 抗癌剤の効果増強剤 |
| JP2011144190A (ja) * | 2004-06-10 | 2011-07-28 | Nippon Kayaku Co Ltd | 抗癌剤の効果増強剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK0904110T3 (da) | 2002-11-11 |
| KR19990087113A (ko) | 1999-12-15 |
| BR9707739A (pt) | 1999-07-27 |
| CA2247848A1 (en) | 1997-09-04 |
| AU706591B2 (en) | 1999-06-17 |
| CA2247848C (en) | 2008-07-15 |
| ITMI960352A0 (enExample) | 1996-02-26 |
| RU2192247C2 (ru) | 2002-11-10 |
| US20040242651A1 (en) | 2004-12-02 |
| IT1282686B1 (it) | 1998-03-31 |
| AU2092497A (en) | 1997-09-16 |
| ES2180938T3 (es) | 2003-02-16 |
| US7087588B2 (en) | 2006-08-08 |
| WO1997031654A1 (en) | 1997-09-04 |
| DE69714253T2 (de) | 2003-03-06 |
| PT904110E (pt) | 2002-12-31 |
| EP0904110A1 (en) | 1999-03-31 |
| HUP9900993A3 (en) | 2000-10-30 |
| DE69714253D1 (de) | 2002-08-29 |
| EP0904110B1 (en) | 2002-07-24 |
| EP1221326A3 (en) | 2004-01-14 |
| HUP9900993A2 (hu) | 1999-09-28 |
| ITMI960352A1 (it) | 1997-08-26 |
| ATE220920T1 (de) | 2002-08-15 |
| EP1221326A2 (en) | 2002-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0904110B1 (en) | Nitric oxide donors capable of reducing toxicity from drugs | |
| Davis et al. | Nimesulide: an update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy | |
| LU87867A1 (fr) | Agents bloquants de l'effect ou de la formation du facteur edrf pour le traitement des chocs | |
| JPH06508849A (ja) | 低血圧症患者に投与する昇圧剤を増強する一酸化窒素合成阻害剤 | |
| JP2004512318A (ja) | Ｃ−ニトロソ化合物とその使用 | |
| JPH11509547A (ja) | Ｌ−ドーパエチルエステルの医薬組成品 | |
| CN101506143A (zh) | 具有快速皮肤穿透速度的带正电荷的水溶性的对乙酰氨基酚及其相关化合物的前药 | |
| WO1997020553A1 (en) | Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists | |
| JP2002521329A (ja) | フェニルアセチルグルタミン、フェニルアセチルイソグルタミンおよび／または酢酸フェニルの投与のための治療管理 | |
| JP3546227B2 (ja) | グルタミンを用いるグルタチオンレベルの増大法 | |
| JPH09501653A (ja) | 薬学的組成物 | |
| FR2797767A1 (fr) | Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances | |
| Hu et al. | Determination of absorption characteristics of AG337, a novel thymidylate synthase inhibitor, using a perfused rat intestinal model | |
| US20090221473A1 (en) | Antitumor agents | |
| WO2021074284A1 (fr) | Utilisation de nictotinamide mononucléotide (nmn) pour la prevention et/ou le traitement de la polyarthrite rhumatoïde et compositions correspondantes | |
| WO2001012204A2 (en) | Xanthine oxidase inhibitor containing compositions for the treatment of acetaminophen intoxication | |
| JP2002537325A (ja) | ＮＦ−κＢの活性化を阻害することにより治療上の影響を与えることができる、ヒトおよび動物における病気を治療するための医薬を製造するためのＲ−アリールプロピオン酸の使用 | |
| HU226567B1 (en) | Use of phenylhydrazon derivates for the preparation of medicaments for the inhibition of neurogenic and non-neurogenic inflammations and for the alleviation of pain | |
| CN1207042A (zh) | 用于治疗自身免疫性疾病的药物组合物 | |
| EP0617959B1 (en) | Pharmaceutical for the treatment of skin disorders | |
| JP2000508308A (ja) | 内皮機能の正常化、性的機能障害、糖尿病の血管合併症及び内皮起源の血管障害の治療用の医薬の製造のための２，５―ジヒドロキシベンゼンスルホン酸誘導体の使用 | |
| AU2005270573B2 (en) | Novel formulation for L-tryptophane comprising carbidopa/benserazide | |
| Rainsford et al. | Recent pharmacodynamic and pharmacokinetic findings on oxaprozin | |
| Chen et al. | Role of L-arginine-derived nitric oxide in cholinergic dilation of gastric arterioles | |
| AU2007271980A1 (en) | Use of fosfluridine tidoxil (FT) for the treatment of intraepithelial proliferative diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040223 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040223 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070306 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070605 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070925 |